ClinicalTrials.gg

Program

HN2301

A development code. Also written as “HN2301 injection”.

Its studies are mostly in Myasthenia Gravis · Lupus Erythematosus, Systemic, led by Shenzhen MagicRNA Biotechnology.

Furthest: phase 1, since Jan 15, 20253 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen MagicRNA Biotechnology32 open or runningphase 1since Jan 15, 2025Jan 15, 2025May 31, 2027phase 1 · NCT07556120

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2025First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT06801119 · 30 planned · China
  2. Apr 29, 2025No phase study in Myasthenia GravisNCT06965309 · 9 enrolled · China
  3. Apr 16, 2026Phase 1 study in Myasthenia GravisNCT07556120 · 6 planned · China

Ahead

  1. May 31, 2027Primary completion: phase 1 study in Myasthenia GravisNCT07556120
  2. Dec 31, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06801119

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07556120Myasthenia Gravis · China1Not yet recruitingMay 31, 20276
NCT06965309Myasthenia Gravis · China–TerminatedFeb 11, 20269
NCT06801119Lupus Erythematosus, Systemic · China1RecruitingDec 31, 202730

How it is read

Names in the registry

  • “HN2301 injection”, 3 entries

Codes read as this program: HN2301.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.